logo

International Journal
of Pharmaceutical Sciences and Drug Research ISSN: 0975-248X | DOI Prefix: 10.25004 | CODEN (USA): IJPSPP

Volume No.: 9 (2017) Issue No: 4

International Journal of Pharmaceutical Sciences and Drug Research 2017; 9(4): 149-159 http://dx.doi.org/10.25004/IJPSDR.2017.090401
Research Article

Optimization of Cilnidipine Nanosuspension Using a Center Composite Design

SK Nagar1*, MM Soniwala2

1School of Pharmacy, RK University, Rajkot - 360 020, Gujarat, India

2B. K. Mody Government Pharmacy College, Rajkot - 360 003, Gujarat, India

 

*Corresponding author: Mrs. Swati Nagar

Address: School of Pharmacy, RK University, Rajkot - 360 020, Gujarat, India

E-mail *: swati.nagar28@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 30 January, 2017; Revised: 05 June, 2017; Accepted: 14 June 2017; Published: 24 July 2017

 

Copyright © 2017 SK Nagar et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

ABSTRACT

The purpose of this investigation was to increase the solubility and dissolution rate of Cilnidipine by the preparation of nanosuspensions with solvent antisolvent method at the laboratory scale. Drug solution of Cilnidipine in acetone this mixture was added to stabilizer solution under continuous homogenization. Central composite design was employed to study the effect of the independent variables on the dependent The relationship between the dependent and independent variables was further Elucidated using multiple liner regression analysis (MLRA) and contour plots. Various process and formulation parameters were screened like homogenization speed, solvent to antisolvent ratio, homogenization time, type of stabilizer, concentration of drug and concentration of stabilizer. Physical stability can be enhancing physical stability of this colloidal system; nanosuspensions were freeze dried using D-mannitol. Seven different stabilizers were tried. Among them Poloxamer 407, Poloxamer 188, PVA and Tween 80 yielded nanosuspension in range of 90 to 350 nm. Freeze dried nanosuspensions were filled in capsules to make a deliverable dosage form and almost 100% drug dissolved in 5 minutes. The outcome of this study reveals the immense potential of nanosuspensions for delivery of Cilnidipine by improving its solubility and dissolution rate. These results show that the preparation of Cilnidipine-loaded nanosuspensions significantly improved the in vitro dissolution rate, thus possibly enhancing the fast onset of therapeutic drug effect.

Keywords: Nanosuspension, Cilnidipine, Dissolution, Solubility.

REFERENCES


  1. Dhiman S, Thakur GS. Nanosuspension: A recent approach for nano drug delivery system. Int J Curr Pharm Res. 2011; 34:96-101.
  2. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Advanced drug delivery reviews. 2001 Mar 23; 47(1):3-19.
  3. Jyothi BJ, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. Journal of young pharmacists. 2011 Jan 1; 3(1):4-8.
  4. Müller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000; 50(1): 61-77.
  5. Chingunpituk J. Nanosuspension Technology for Drug Delivery. Walailak J Sci & Tech 2007; 4(2): 139-153.
  6. Patel M, Shah A, Patel NM, Patel MR, Patel KR. Nanosuspension: A novel approach for drug delivery system. JPSBR. 2011 Jul; 1(1):1-0.
  7. Patravale VB, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. Journal of pharmacy and pharmacology. 2004 Jul 1;56(7):827-40.
  8. Prabhakar Ch. A Review on Nanosuspension in Drug Delivery. Int J Pharm & Bio Sci. 2011; 2(1): 549-58.
  9. De PK, Chakraborty S, Das S. Nanosuspensions: Potent vehicles for drug delivery and bioavailability enhancement of lipophilic drugs. Journal of Pharmacy Research Vol. 2012 Mar;5(3):1548-54.
  10. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. Journal of Antimicrobial Chemotherapy. 2000 Jan;45(1):77-83.
  11. Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. International journal of pharmaceutics. 2000 Mar 10;196(2):161-4.
  12. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. European Journal of Pharmaceutical Sciences. 2002 Jul 31;16(1):53-61.
  13. Chen Y, Liu J, Yang X, Zhao X, Xu H. Oleanolic acid nanosuspensions: preparation, in‐vitro characterization and enhanced hepatoprotective effect. Journal of pharmacy and pharmacology. 2005 Feb 1;57(2):259-64.
  14. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, Yun J. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. International journal of pharmaceutics. 2006 Oct 12;323(1):153-60.
  15. Zhang X, Xia Q, Gu N. Preparation of all-trans retinoic acid nanosuspensions using a modified precipitation method. Drug development and industrial pharmacy. 2006 Jan 1;32(7):857-63.
  16. Parchri BD, Shantha GS. Formulation and evaluation of nanoparticulate drug delivery system of acyclovir for topical drug delivery. World Journal of Pharmacy and Pharmaceutical Science. 2013 Sep 3;2(6):5602-17.
  17. Mhetre RL, Hol VB, Bajaj AN, Jadhav RB. Arteether-loaded solid lipid nanoparticulate dispersion: design and characterization. World J. Pharm. Pharm. Sci. 2013 Aug 20;2:5011-9.
  18. Nair R, Kumar AC, Priya VK, Yadav CM, Raju PY. Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine. Lipids in health and disease. 2012 Jun 13;11(1):72.
  19. Chirio D, Gallarate M, Peira E, Battaglia L, Serpe L, Trotta M. Formulation of curcumin-loaded solid lipid nanoparticles produced by fatty acids coacervation technique. Journal of microencapsulation. 2011 Sep 1;28(6):537-48.
  20. Rupavath M, Patnaik K. Development and in vitro characterization gastro retentive raft forming stavudine tablets. Int. J. Pharm. Sci. Drug Res. 2017; 9(1):01-09.
  21. Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. International Journal of Pharmaceutics. 2010 Oct 31;399(1):129-39.
  22. Lakshmi P, Kumar GA. Nanosuspension Technology: A Review. Int J Pharm & Pharm Sci. 2010; 2: 35-40.
  23. Kumar P, Krishna KG. Nanosuspensions: the solution to deliver hydrophobic drugs. International Journal of Drug Delivery. 2011 Oct 1;3(4):546.
  24. Dhiman S, Thakur GS. Nanosuspension: A recent approach for nano drug delivery system. Int J Curr Pharm Res. 2011;34:96-101.
  25. Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. Aaps Pharmscitech. 2006 Mar 1;7(1):E192-8.
  26. Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. International journal of pharmaceutics. 2000 Mar 10;196(2):161-4.
  27. Arunkumar N, Deecaraman M, Rani C, Mohanraj KP, Kumar KV. Preparation and solid state characterization of atorvastatin nanosuspensions for enhanced solubility and dissolution. Int J Pharm Tech Res. 2009;1(4):1725-30.
  28. Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharmaceutical research. 2002 Feb 1;19(2):189-94.
  29. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. International journal of pharmaceutics. 2003 Mar 18;254(1):73-5.
  30. Trotta M, Gallarate M, Carlotti ME, Morel S. Preparation of griseofulvin nanoparticles from water-dilutable microemulsions. International journal of pharmaceutics. 2003 Mar 26;254(2):235-42.
  31. Möschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. European Journal of Pharmaceutics and Biopharmaceutics. 2004 Nov 30;58(3):615-9.